Narsoplimab Exceeds Expectations Across High-Risk HSCT-TMA Subtype

May 14, 2021

Administered narsoplimab in patients with high-risk hematopoietic stem cell transplant– associated thrombotic microangiopathy resulted in a response rate of 61% among all patients treated with the monoclonal antibody

PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate Cancer

May 14, 2021

With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant disease, the ability to detect and treat the disease has been transformed.